Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Summary
Capricor announced positive five-year extension data and Phase 3 results for Deramiocel in Duchenne muscular dystrophy. The company says the therapy showed durable skeletal and cardiac benefits, a favorable safety profile, and statistically significant outcomes in the HOPE-3 trial. Capricor plans to present the data at the PPMD 2026 Annual Conference. The release also notes that the BLA is under FDA review and that the company is working toward an August 22, 2026 PDUFA target date.
Classifications
industries
No industries detected
applications
No applications detected
AI Classifications
Labels
No AI classifications detected